ketamine has been researched along with Social Anxiety Disorder in 4 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment." | 9.27 | Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. ( Glue, P; Gray, A; Kibby, G; McNaughton, N; Medlicott, NJ; Neehoff, SM, 2018) |
| "Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders." | 8.02 | Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. ( Glue, P; Gray, A; Neehoff, S; Nehoff, H; Truppman Lattie, D, 2021) |
| "Ketamine may achieve its effects on treatment-resistant generalized anxiety disorder and social anxiety disorder through related mechanisms to the common reduction by conventional anxiolytic drugs in right frontal theta." | 7.88 | Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety. ( Glue, P; Kawe, T; Martin, D; McNaughton, N; Neehoff, S; Shadli, SM, 2018) |
| "Ketamine is a potent N-methyl-D-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders." | 6.87 | Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. ( Bloch, MH; Coughlin, C; Gabriel, D; Jakubovski, E; Johnson, JA; Landeros-Weisenberger, A; Mulqueen, J; Reed, MO; Taylor, JH, 2018) |
| "In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment." | 5.27 | Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. ( Glue, P; Gray, A; Kibby, G; McNaughton, N; Medlicott, NJ; Neehoff, SM, 2018) |
| "Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders." | 4.02 | Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. ( Glue, P; Gray, A; Neehoff, S; Nehoff, H; Truppman Lattie, D, 2021) |
| "Ketamine may achieve its effects on treatment-resistant generalized anxiety disorder and social anxiety disorder through related mechanisms to the common reduction by conventional anxiolytic drugs in right frontal theta." | 3.88 | Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety. ( Glue, P; Kawe, T; Martin, D; McNaughton, N; Neehoff, S; Shadli, SM, 2018) |
| "Ketamine is a potent N-methyl-D-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders." | 2.87 | Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. ( Bloch, MH; Coughlin, C; Gabriel, D; Jakubovski, E; Johnson, JA; Landeros-Weisenberger, A; Mulqueen, J; Reed, MO; Taylor, JH, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Truppman Lattie, D | 1 |
| Nehoff, H | 1 |
| Neehoff, S | 2 |
| Gray, A | 2 |
| Glue, P | 3 |
| Taylor, JH | 1 |
| Landeros-Weisenberger, A | 1 |
| Coughlin, C | 1 |
| Mulqueen, J | 1 |
| Johnson, JA | 1 |
| Gabriel, D | 1 |
| Reed, MO | 1 |
| Jakubovski, E | 1 |
| Bloch, MH | 1 |
| Neehoff, SM | 1 |
| Medlicott, NJ | 1 |
| Kibby, G | 1 |
| McNaughton, N | 2 |
| Shadli, SM | 1 |
| Kawe, T | 1 |
| Martin, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ketamine Infusion for Social Anxiety Disorder[NCT02083926] | Early Phase 1 | 18 participants (Actual) | Interventional | 2015-01-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 66.1 |
| Saline Infusion on Day 0 or Day 28 | 86.1 |
"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 12.1 |
| Saline Infusion on Day 0 or Day 28 | 19.6 |
2 trials available for ketamine and Social Anxiety Disorder
| Article | Year |
|---|---|
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.
Topics: Adult; Anti-Anxiety Agents; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonis | 2018 |
Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Drug Resistance; Female; Humans; In | 2018 |
2 other studies available for ketamine and Social Anxiety Disorder
| Article | Year |
|---|---|
Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Double-Blind Method; Fear; Female; Humans; Ketamine | 2021 |
Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety; Brain; Dose-Response Relationship, Drug; Doub | 2018 |